glp-1 and kidney receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal GLP-1 agonists in the treatment

All other agents are selective GLP-1 RAs

Noom pairs sustainable behavior change with prescription-grade catalysts to make lasting change feel easy

Reassuring clinical data are starting to accrue: two multinational population-based cohort studies found no increased risk of major congenital malformations, live births, pregnancy losses, and pregnancy terminations during the periconceptional period with GLP-1 RAs [139]

Tirzepatide can cause anxiety in some users, and hormone imbalances can do the same

For some patients, one medication may be more appropriate than the other depending on their health history, treatment goals, and how their body responds to therapy

The effects of exogenous GLP-1 after administration to T2DM patients show improved insulin sensitivity, decreased glucagon concentration, slowed gastric emptying, increased satiety, decreased fatty acid concentration, lowered body weight, and overall decreased hemoglobin A1c (HBA1c) levels